Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.42 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21273903 | 1.00 | ABCB1 (0.54) | ABCB1KLK7FKBP1AMCL1UCHL1 | |
| SCHEMBL1448111 | 1.00 | ABCB1 (0.54) | ABCB1KLK7FKBP1AMCL1UCHL1 | |
| SCHEMBL7279798 | 1.00 | ABCB1 (0.54) | ABCB1KLK7FKBP1AMCL1UCHL1 | |
| SCHEMBL475486 | 0.91 | ABCB1 (0.52) | ABCB1KLK7MCL1UCHL1AGTR2 | |
| SCHEMBL3854950 | 0.91 | ABCB1 (0.52) | ABCB1KLK7MCL1UCHL1AGTR2 | |
| SCHEMBL18093988 | 0.91 | ABCB1 (0.52) | ABCB1KLK7MCL1UCHL1AGTR2 | |
| SCHEMBL3191348 | 0.91 | ABCB1 (0.52) | ABCB1KLK7MCL1UCHL1AGTR2 | |
| SCHEMBL475487 | 0.91 | ABCB1 (0.52) | ABCB1KLK7MCL1UCHL1AGTR2 | |
| SCHEMBL16064932 | 0.91 | ABCB1 (0.47) | ABCB1KLK7FKBP1AMCL1UCHL1 | |
| SCHEMBL15417732 | 0.90 | ABCB1 (0.48) | ABCB1KLK7FKBP1AMCL1UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678238-A2 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| US-20250313578-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2025-10-09 | — | — | US | disclosed |
| EP-3752251-B1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | PRELUDE THERAPEUTICS INCORPORATED | 2025-09-04 | — | — | US | disclosed |
| EP-4587127-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics Incorporated (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12195485-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2025-01-14 | — | — | US | disclosed |
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-23 | — | — | US | disclosed |
| WO-2024059806-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024059806-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11912727-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2024-02-27 | — | — | US | disclosed |
| CN-117180290-A | Arginase inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230365599-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2023-11-16 | — | — | US | disclosed |
| US-20230365599-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2023-11-16 | — | — | US | disclosed |
| CN-111712302-B | Arginase inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116239591-A | (4R) -sulfonamido-L-prolinamide compound, preparation method, application and pharmaceutical composition thereof | 嘉兴学院 | 2023-06-09 | — | — | CN | disclosed |
| US-20230122859-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-11420984-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2022-08-23 | — | — | US | disclosed |
| US-6362165-B1 | Hydroxyphenyl derivatives with HIV integrase inhibitory properties | PHARMACOR INC. (CA) | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912727-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ABCB1 870/4885KLK7 4255/4885FKBP1A 2774/4885 |
| US-12195485-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, PRMT1 | ABCB1 815/4885KLK7 4347/4885FKBP1A 2702/4885 |
| US-20230122859-A1 | Arginase Inhibitors and Methods of Use Thereof | ARG1, ARG2, PRMT1 | ABCB1 815/4885KLK7 4347/4885FKBP1A 2702/4885 |
| US-20230365599-A1 | Arginase Inhibitors and Methods of Use Thereof | ARG1, ARG2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ABCB1 870/4885KLK7 4255/4885FKBP1A 2774/4885 |
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | ABCG2, BRIX1, MRPS28 | ABCB1 4/4885KLK7 2115/4885FKBP1A 3447/4885 |
| US-20250313578-A1 | Arginase Inhibitors and Methods of Use Thereof | ARG1, ARG2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ABCB1 870/4885KLK7 4255/4885FKBP1A 2774/4885 |
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | CRBN, RBX1, SMARCE1 | ABCB1 357/4885KLK7 4007/4885FKBP1A 4539/4885 |
| US-11420984-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ABCB1 863/4885KLK7 4247/4885FKBP1A 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.